

# Patrick S Parfrey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2191559/publications.pdf>

Version: 2024-02-01

158  
papers

15,660  
citations

34105

52  
h-index

16650

123  
g-index

162  
all docs

162  
docs citations

162  
times ranked

11432  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	15
2	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.7	20
3	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	2.7	9
4	Changing Health-Related Behaviors 2: On Improving the Value of Health Spending. <i>Methods in Molecular Biology</i> , 2021, 2249, 553-569.	0.9	1
5	Changing Health-Related Behaviors 4: Realizing Impact of Health Research Through Knowledge Translation. <i>Methods in Molecular Biology</i> , 2021, 2249, 597-612.	0.9	1
6	Longitudinal Studies 3: Data Modeling Using Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2021, 2249, 125-165.	0.9	0
7	Randomized Controlled Trials 7: On Contamination and Estimating the Actual Treatment Effect. <i>Methods in Molecular Biology</i> , 2021, 2249, 307-318.	0.9	0
8	Randomized Controlled Trials 1: Design. <i>Methods in Molecular Biology</i> , 2021, 2249, 193-211.	0.9	1
9	Bias in Clinical Research. <i>Methods in Molecular Biology</i> , 2021, 2249, 17-34.	0.9	6
10	Randomized Controlled Trials 2: Analysis. <i>Methods in Molecular Biology</i> , 2021, 2249, 213-227.	0.9	0
11	Randomized Controlled Trials 4: Planning, Analysis, and Interpretation of Quality-of-Life Studies. <i>Methods in Molecular Biology</i> , 2021, 2249, 247-259.	0.9	1
12	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	12.1	44
13	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <i>Kidney International Reports</i> , 2021, 6, 1130-1140.	0.8	1
14	Variation and appropriateness of antipsychotic use in long-term care facilities across Newfoundland and Labrador. <i>Canadian Pharmacists Journal</i> , 2021, 154, 205-212.	0.8	0
15	Nongenetic Determinants of Risk for Early-Onset Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab029.	2.9	39
16	A comprehensive analysis of SNPs and CNVs identifies novel markers associated with disease outcomes in colorectal cancer. <i>Molecular Oncology</i> , 2021, 15, 3329-3347.	4.6	9
17	Prediagnostic consumption of vitamin D, calcium and dairy products and colorectal cancer survival: results from the Newfoundland Colorectal Cancer Registry Cohort Study. <i>British Journal of Nutrition</i> , 2021, , 1-10.	2.3	4
18	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2021, 2249, 1-16.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Longitudinal Studies 2: Modeling Data Using Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2021, 2249, 103-124.	0.9	1
20	Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. <i>International Journal of Cancer</i> , 2020, 146, 861-873.	5.1	89
21	Joint nested frailty models for clustered recurrent and terminal events: An application to colonoscopy screening visits and colorectal cancer risks in Lynch Syndrome families. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1466-1479.	1.5	5
22	Sustainability of an Enhanced Recovery After Surgery initiative for elective colorectal resections in a community hospital. <i>Canadian Journal of Surgery</i> , 2020, 63, E292-E298.	1.2	7
23	Are general practitioners referring patients with low back pain for CTs appropriately according to the guidelines: a retrospective review of 3609 medical records in Newfoundland using routinely collected data. <i>BMC Family Practice</i> , 2020, 21, 236.	2.9	10
24	Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. <i>Cancer Research</i> , 2020, 80, 4578-4590.	0.9	26
25	Exercise and arrhythmic risk in TMEM43 p.S358L arrhythmogenic right ventricular cardiomyopathy. <i>Heart Rhythm</i> , 2020, 17, 1159-1166.	0.7	16
26	Family physician referral rates for lumbar spine computed tomography in Newfoundland and Labrador: a cross-sectional analysis using routinely collected data. <i>CMAJ Open</i> , 2020, 8, E56-E59.	2.4	1
27	The effect of laboratory requisition modification, audit and feedback with academic detailing or both on utilization of blood urea testing in family practice in Newfoundland, Canada. <i>Clinical Biochemistry</i> , 2020, 83, 21-27.	1.9	2
28	The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effects. <i>BMC Medicine</i> , 2019, 17, 150.	5.5	32
29	A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 133.	2.6	13
30	What do we really know about the appropriateness of radiation emitting imaging for low back pain in primary and emergency care? A systematic review and meta-analysis of medical record reviews. <i>PLoS ONE</i> , 2019, 14, e0225414.	2.5	10
31	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	1.9	18
32	Title is missing!. , 2019, 14, e0225414.		0
33	Title is missing!. , 2019, 14, e0225414.		0
34	Title is missing!. , 2019, 14, e0225414.		0
35	Title is missing!. , 2019, 14, e0225414.		0
36	Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney International</i> , 2018, 93, 1475-1482.	5.2	41

#	ARTICLE	IF	CITATIONS
37	Impact of colonoscopic screening in Familial Colorectal Cancer Type X. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2018, 6, 1021-1030.	1.2	10
38	Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. <i>Kidney International</i> , 2018, 94, 661-662.	5.2	0
39	Hypothesis and data-driven dietary patterns and colorectal Cancer survival: findings from Newfoundland and Labrador colorectal Cancer cohort. <i>Nutrition Journal</i> , 2018, 17, 55.	3.4	18
40	Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses. <i>Biomarker Research</i> , 2018, 6, 17.	6.8	5
41	Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake. <i>BMC Cancer</i> , 2018, 18, 155.	2.6	8
42	Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0198873.	2.5	6
43	XRCC3 Thr241Met and TYMS variable number tandem repeat polymorphisms are associated with time-to-metastasis in colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0192316.	2.5	6
44	Germline <sc>INDEL</sc>s and <sc>CNV</sc>s in a cohort of colorectal cancer patients: their characteristics, associations with relapse-free survival time, and potential time-varying effects on the risk of relapse. <i>Cancer Medicine</i> , 2017, 6, 1220-1232.	2.8	14
45	Two phospho targets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 965-973.	4.5	25
46	Inflammatory diet and risk for colorectal cancer: A population-based case-control study in Newfoundland, Canada. <i>Nutrition</i> , 2017, 42, 69-74.	2.4	24
47	Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population. <i>British Journal of Cancer</i> , 2017, 117, 898-906.	6.4	18
48	Change in Hemoglobin Trajectory and Darbeoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	3.1	8
49	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	24
50	Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in <i>TMEM43</i> Following Implantable Cardioverter Defibrillator Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	37
51	The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. <i>Contemporary Clinical Trials</i> , 2016, 48, 119-124.	1.8	21
52	No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients. <i>Cancer Medicine</i> , 2016, 5, 2221-2231.	2.8	6
53	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	1.9	28
54	Analyzing Health-Related Quality of Life in the EVOLVE Trial. <i>Medical Decision Making</i> , 2016, 36, 965-972.	2.4	19

#	ARTICLE	IF	CITATIONS
55	Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. BMC Cancer, 2016, 16, 113.	2.6	7
56	Genetic structure of the Newfoundland and Labrador population: founder effects modulate variability. European Journal of Human Genetics, 2016, 24, 1063-1070.	2.8	22
57	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 539-546.	4.5	20
58	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health, 2015, 18, 1079-1087.	0.3	16
59	Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. Pharmaceutical Statistics, 2015, 14, 242-251.	1.3	17
60	A Survival Association Study of 102 Polymorphisms Previously Associated with Survival Outcomes in Colorectal Cancer. BioMed Research International, 2015, 2015, 1-9.	1.9	5
61	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 791-799.	4.5	75
62	Community engagement with genetics: public perceptions and expectations about genetics research. Health Expectations, 2015, 18, 1413-1425.	2.6	30
63	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation, 2015, 132, 27-39.	1.6	259
64	A genome wide association study on Newfoundland colorectal cancer patients'™ survival outcomes. Biomarker Research, 2015, 3, 6.	6.8	17
65	The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 800-807.	4.5	107
66	Mitochondrial DNA polymorphisms, its copy number change and outcome in colorectal cancer. BMC Research Notes, 2015, 8, 272.	1.4	16
67	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1466-1475.	6.1	163
68	Cardiovascular Disease and Chronic Kidney Disease. , 2015, , 181-198.		2
69	On Framing the Research Question and Choosing the Appropriate Research Design. Methods in Molecular Biology, 2015, 1281, 3-18.	0.9	4
70	Randomized Controlled Trials 6: On Contamination and Estimating the Actual Treatment Effect. Methods in Molecular Biology, 2015, 1281, 249-259.	0.9	2
71	Dietary<i>N</i>-nitroso compounds and risk of colorectal cancer: a case&quot;control study in Newfoundland and Labrador and Ontario, Canada. British Journal of Nutrition, 2014, 111, 1109-1117.	2.3	82
72	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Journal of the American Heart Association, 2014, 3, e001363.	3.7	105

#	ARTICLE	IF	CITATIONS
73	Cardiac Biomarkers and Health-Related Quality of Life in New Hemodialysis Patients without Symptomatic Cardiac Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 16.	1.1	9
74	Examining the Polymorphisms in the Hypoxia Pathway Genes in Relation to Outcome in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e113513.	2.5	7
75	Development and preliminary testing of the psychosocial adjustment to hereditary diseases scale. <i>BMC Psychology</i> , 2013, 1, 7.	2.1	1
76	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQqO 0.0 rgBT /Overlock 10 Diseases, 2013, 61, 238-246.	1.9	21
77	On Peginesatide and Anemia Treatment in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 659-661.	1.9	4
78	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.	3.6	63
79	Why does the treatment of anaemia not improve cardiac outcomes in CKD?. <i>Nature Reviews Nephrology</i> , 2013, 9, 59-61.	9.6	2
80	MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland. <i>PLoS ONE</i> , 2013, 8, e61469.	2.5	30
81	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.7	45
82	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	27.0	805
83	Interaction between alcohol drinking and obesity in relation to colorectal cancer risk: a case-control study in Newfoundland and Labrador, Canada. <i>BMC Public Health</i> , 2012, 12, 94.	2.9	25
84	Sudden cardiac death in chronic kidney disease: epidemiology and prevention. <i>Nature Reviews Nephrology</i> , 2011, 7, 145-154.	9.6	118
85	Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa. <i>Circulation</i> , 2011, 124, 2903-2908.	1.6	89
86	Promoter methylation of Wnt antagonists <i>DKK1</i> and <i>SFRP1</i> is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. <i>Carcinogenesis</i> , 2011, 32, 741-747.	2.8	74
87	Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 177-181.	2.0	22
88	Erythropoietin-Stimulating Agents in Chronic Kidney Disease: A Response to Hyporesponsiveness. <i>Seminars in Dialysis</i> , 2011, 24, 495-497.	1.3	3
89	Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 845-855.	4.5	53
90	Quality of Life in CKD Patients Treated With Erythropoiesis-Stimulating Agents. <i>American Journal of Kidney Diseases</i> , 2010, 55, 423-425.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 1146-1155.	27.0	433
92	Left Ventricular Hypertrophy in New Hemodialysis Patients without Symptomatic Cardiac Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 805-813.	4.5	125
93	Editorial Perspective. Should Hemoglobin Targets for Anemic Patients with Chronic Kidney Disease Be Changed. <i>American Journal of Nephrology</i> , 2010, 31, 565-566.	3.1	1
94	Specific Variants in the MLH1 Gene Region May Drive DNA Methylation, Loss of Protein Expression, and MSI-H Colorectal Cancer. <i>PLoS ONE</i> , 2010, 5, e13314.	2.5	35
95	Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 755-762.	4.5	102
96	Autosomal recessive Bardet-Biedl syndrome: first-degree relatives have no predisposition to metabolic and renal disorders. <i>Kidney International</i> , 2009, 76, 215-223.	5.2	14
97	Translation of research discoveries to clinical care in arrhythmogenic right ventricular cardiomyopathy in Newfoundland and Labrador: Lessons for health policy in genetic disease. <i>Genetics in Medicine</i> , 2009, 11, 859-865.	2.4	18
98	Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 726-733.	4.5	64
99	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	27.0	2,110
100	Mechanisms of the cardiorenal syndromes. <i>Nature Reviews Nephrology</i> , 2009, 5, 641-649.	9.6	69
101	Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 16.	1.5	9
102	Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Is a Fully Penetrant, Lethal Arrhythmic Disorder Caused by a Missense Mutation in the TMEM43 Gene. <i>American Journal of Human Genetics</i> , 2008, 82, 809-821.	6.2	431
103	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2008, 473, 1-17.	0.9	10
104	Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1669-1675.	4.5	33
105	Bias in Clinical Studies of Genetic Diseases. <i>Methods in Molecular Biology</i> , 2008, 473, 171-186.	0.9	0
106	Clinical research of kidney diseases II: problems of study design. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2785-2794.	0.7	15
107	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 898-905.	4.5	144
108	In the Literature: On Clinical Performance Measures and Outcomes Among Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2007, 49, 352-355.	1.9	8

#	ARTICLE	IF	CITATIONS
109	The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome. <i>Familial Cancer</i> , 2007, 6, 1-12.	1.9	34
110	Target Hemoglobin Level for EPO Therapy in CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 171-173.	1.9	20
111	Therapy Insight: management of cardiovascular disease in the renal transplant recipient. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 514-526.	2.0	14
112	Incident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease: A Population and Family-Based Cohort Followed for 22 Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 710-717.	4.5	67
113	Autosomal-recessive polycystic kidney disease. <i>Kidney International</i> , 2005, 67, 1638-1648.	5.2	13
114	Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: A 22-year prospective, population-based, cohort study. <i>American Journal of Medical Genetics, Part A</i> , 2005, 132A, 352-360.	1.2	249
115	The Clinical Epidemiology of Contrast-Induced Nephropathy. <i>CardioVascular and Interventional Radiology</i> , 2005, 28, S3-S11.	2.0	95
116	Linkage disequilibrium mapping in the Newfoundland population: a re-evaluation of the refinement of the Bardet-Biedl syndrome 1 critical interval. <i>Human Genetics</i> , 2005, 116, 62-71.	3.8	3
117	Antibiotic utilisation in community practices: guideline concurrence and prescription necessity. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 319-326.	1.9	17
118	High Frequency of Hereditary Colorectal Cancer in Newfoundland Likely Involves Novel Susceptibility Genes. <i>Clinical Cancer Research</i> , 2005, 11, 6853-6861.	7.0	46
119	Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2180-2189.	6.1	343
120	An evaluation of acute care restructuring in Newfoundland and Labrador: conclusions. <i>Journal of Health Services Research and Policy</i> , 2005, 10, 71-73.	1.7	0
121	Rationale Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005, 149, 408-413.	2.7	115
122	The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). <i>Journal of the American College of Cardiology</i> , 2005, 45, 400-408.	2.8	164
123	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Introduction. <i>Seminars in Dialysis</i> , 2003, 16, 83-84.	1.3	7
124	Electrocardiographic Left Ventricular Hypertrophy in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 462-468.	6.1	182
125	Clinical and genetic epidemiology of inherited renal disease in Newfoundland. <i>Kidney International</i> , 2002, 61, 1925-1934.	5.2	34
126	Congestive Heart Failure in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1084-1090.	6.1	241



#	ARTICLE	IF	CITATIONS
127	Bilineal Disease and Trans-Heterozygotes in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Human Genetics</i> , 2001, 68, 355-363.	6.2	146
128	Genetic and Mutational Analyses of a Large Multiethnic Bardet-Biedl Cohort Reveal a Minor Involvement of BBS6 and Delineate the Critical Intervals of Other Loci. <i>American Journal of Human Genetics</i> , 2001, 68, 606-616.	6.2	80
129	Factors Governing Cardiovascular Risk in the Patient with a Failing Renal Transplant. <i>Peritoneal Dialysis International</i> , 2001, 21, 275-279.	2.3	75
130	Left Ventricular Hypertrophy in the Renal Patient. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1079-1084.	6.1	235
131	Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. <i>Kidney International</i> , 2000, 58, 1325-1335.	5.2	357
132	Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. <i>Nature Genetics</i> , 2000, 25, 143-144.	21.4	116
133	Mutations in MKKS cause Bardet-Biedl syndrome. <i>Nature Genetics</i> , 2000, 26, 15-16.	21.4	256
134	Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. <i>Nature Genetics</i> , 2000, 26, 67-70.	21.4	311
135	Community pharmacist outreach program directed at physicians treating congestive heart failure. <i>American Journal of Health-System Pharmacy</i> , 2000, 57, 747-752.	1.0	13
136	Contrast Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 177-182.	6.1	319
137	Serial Change in Echocardiographic Parameters and Cardiac Failure in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 912-916.	6.1	208
138	Pathogenesis of Cardiac Disease in Dialysis Patients. <i>Seminars in Dialysis</i> , 1999, 12, 62-68.	1.3	20
139	Anemia as a Risk Factor for Cardiac Disease in Dialysis Patients. <i>Seminars in Dialysis</i> , 1999, 12, 84-86.	1.3	1
140	A Fifth Locus for Bardet-Biedl Syndrome Maps to Chromosome 2q31. <i>American Journal of Human Genetics</i> , 1999, 64, 900-904.	6.2	117
141	A Founder Effect in the Newfoundland Population Reduces the Bardet-Biedl Syndrome I (BBS1) Interval to 1 cM. <i>American Journal of Human Genetics</i> , 1999, 65, 1680-1687.	6.2	45
142	Genetic Heterogeneity of Bardet-Biedl Syndrome in a Distinct Canadian Population: Evidence for a Fifth Locus. <i>Genomics</i> , 1999, 55, 2-9.	2.9	63
143	Somatic PKD2 Mutations in Individual Kidney and Liver Cysts Support a "Two-Hit" Model of Cystogenesis in Type 2 Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1524-1529.	6.1	145
144	Canadian Bardet-Biedl syndrome family reduces the critical region of BBS3 (3p) and presents with a variable phenotype. <i>American Journal of Medical Genetics Part A</i> , 1998, 78, 461-467.	2.4	49

#	ARTICLE	IF	CITATIONS
145	Risk Factors for Cardiac Dysfunction in Dialysis Patients: Implications for Patient Care. <i>Seminars in Dialysis</i> , 1997, 10, 137-141.	1.3	3
146	The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 1996, 28, 53-61.	1.9	699
147	The importance of renal impairment in the natural history of bardet-biedl syndrome. <i>American Journal of Kidney Diseases</i> , 1996, 27, 776-783.	1.9	120
148	Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. <i>Kidney International</i> , 1995, 47, 884-890.	5.2	605
149	Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. <i>Kidney International</i> , 1995, 47, 186-192.	5.2	1,094
150	Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. <i>Kidney International</i> , 1994, 46, 1118-1123.	5.2	69
151	Autosomal dominant polycystic kidney disease: New information for genetic counselling. <i>American Journal of Medical Genetics Part A</i> , 1992, 43, 548-553.	2.4	107
152	Left Ventricular Hypertrophy in Dialysis Patients. <i>Seminars in Dialysis</i> , 1992, 5, 34-41.	1.3	19
153	Autosomal Dominant Polycystic Kidney Disease and End Stage Renal Disease. <i>Seminars in Dialysis</i> , 1991, 4, 26-32.	1.3	5
154	The Diagnosis and Prognosis of Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 1990, 323, 1085-1090.	27.0	331
155	The Cardinal Manifestations of Bardet-Biedl Syndrome, a Form of Laurence-Moon-Biedl Syndrome. <i>New England Journal of Medicine</i> , 1989, 321, 1002-1009.	27.0	527
156	Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both. <i>New England Journal of Medicine</i> , 1989, 320, 143-149.	27.0	957
157	The Spectrum of Renal Disease in Laurence-Moon-Biedl Syndrome. <i>New England Journal of Medicine</i> , 1988, 319, 615-618.	27.0	156
158	Radiocontrast Nephropathy. , 0, , 110-121.		0